Journal of Clinical Research in Oncology
Volume 4, Issue 1, 2021, Page No: 1-9

EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment

Weiyu Wang1,2, Jian Li3, Shengyao Ma1,2, Hanyue Li1, Zhiqin Gao1, Meihua Qu1,2

1. Biopharmaceutical Laboratory, Key Laboratory of Shandong Province Colleges and Universities, School of life science and Technology, Weifang Medical University, 7166 Baotong West Street, Weifang 261053, China.
2. Translational Medical Center, Weifang Second People's Hospital, Weifang Respiratory Disease Hospital, Weifang 261041, China.
3. Department of Pharmacy, Affiliated Hospital of Weifang Medical University, Weifang 261041, China.

Citation : Wang W, Li J, Ma S, Li H, Gao Z, Qu M. EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment. J Clin Res Oncol 2021;4(1):1-9.

Abstract

Epidermal growth factor receptor (EGFR) mutations and EGFR overexpression have become the key factor to the occurrence of non-small cell lung cancer (NSCLC). EGFR tyrosine-protein kinase inhibitors (EGRR-Tyrosine Kinase Inhibitors, EGFR-TKIs) were used in clinic to treat NSCLC by blocking the EGFR signaling pathway. Due to the existence of rare EGFR mutations and secondary mutations under drug load, the first generation, second generation, and third generation of EGFR TKIs have been used in clinical practice. In addition, EGFR secondary mutation and abnormal activation of EGFR downstream signaling molecules or bypass signaling pathways are the reasons for NSCLC resistance to EGFR TKIs. The combination of EGFR TKIs and EGFR downstream signal molecule inhibitors can improve the efficiency of targeted therapy for NSCLC. Based on clarifying the mechanism of resistance of NSCLC to EGFR TKIs, this paper introduces new inhibitors targeting RAS-ERK signaling downstream of EGFR. This paper also reviews progresses in a combination of EGFR TKIs and downstream signal molecule inhibitors in the treatment of NSCLC.


Download Full paper: Click Here